Phylogica Announces Successful Collaboration with Roche
Phylogica Ltd announced successful completion of the initial research objectives of its collaboration with Roche. The objective of the first stage of the research collaboration with Roche was to use Phylogica’s Phylomer drug discovery platform to identify novel cell-penetrating peptides for targeting intracellular disease pathways. Now that Roche has independently validated the cell penetration activities of the Phylomers discovered by Phylogica, the two companies are now discussing the expansion of their collaboration to include in vivo studies for identification of unique Phylomer peptides that cross the blood-brain barrier. The objective of such delivery is to develop novel treatments for neurological disorders using biologics. Phylogica will receive an undisclosed milestone payment to reflect the completion of the first stage of the collaboration with Roche.
“The success of the first stage of our collaboration with Roche provides clear confirmation of the ability of Phylogica’s Phylomers to address key challenges in drug discovery,” said Phylogica’s CEO, Dr Paul Watt. “We are now directing our efforts to investigate peptides that cross the blood-brain barrier. Current biological drugs have limited application as treatments for neurological diseases due to this barrier. We look forward to reporting further progress in this new field over the next few months.”
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
